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Aim: To compare the associations between concomitant liraglutide use versus no liraglutide use
and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among patients
receiving basal insulin (either insulin degludec [degludec] or insulin glargine 100 units/mL [glargine
U100]) in the Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in
Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE).
Materials and Methods: Patients with type 2 diabetes and high cardiovascular risk were ran-
domized 1:1 to degludec or glargine U100. Hazard ratios for MACE/mortality were calculated
using a Cox regression model adjusted for treatment and time-varying liraglutide use at any time
during the trial, without interaction. Sensitivity analyses were adjusted for baseline covariates
including, but not limited to, age, sex, smoking and prior cardiovascular disease.
Results: At baseline, 436/7637 (5.7%) patients were treated with liraglutide; after baseline,
187/7637 (2.4%) started and 210/7637 (2.7%) stopped liraglutide. Mean liraglutide exposure
from randomization was 530.2 days. Liraglutide use versus no liraglutide use was associated
with significantly lower hazard rates for MACE [0.62 (0.41; 0.92)95%CI] and all-cause mortality
[0.50 (0.29; 0.88)95%CI]. There was no significant difference in the rate of severe hypoglycaemia
with versus without liraglutide use. Multiple sensitivity analyses yielded similar results.
Conclusions: Use of liraglutide was associated with significantly lower risk of MACE and death
in patients with type 2 diabetes and high cardiovascular risk using basal insulin.
KEYWORDS
cardiovascular disease, hypoglycaemia, insulin therapy, liraglutide, randomized trial, type
2 diabetes
1 | INTRODUCTION
Diabetes is an independent risk factor for cardiovascular disease, and
cardiovascular complications are the leading causes of diabetes-
related morbidity and mortality.1 Therefore, understanding the car-
diovascular safety of glucose-lowering treatment regimens is partic-
ularly important. In 2008, the US Food and Drug Administration
provided guidance for assessing cardiovascular risk when developing
new antihyperglycaemic medications for the treatment of type 2 dia-
betes.2 Since this guidance was issued, numerous large-scaleAlan C. Moses - Affiliation correct at the time of the trial.
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cardiovascular outcomes trials of antihyperglycaemic medications
have been conducted.
The cardiovascular safety of basal insulin glargine 100 units/mL
(glargine U100) and insulin degludec (degludec) was established by
the open-label ORIGIN and double-blind DEVOTE randomized trials,
respectively, both of which included patients at high risk of cardiovas-
cular events.3,4 In 2011, the final results from the Outcome Reduction
with Initial Glargine Intervention (ORIGIN) trial had shown that glar-
gine U100 did not significantly affect the risk of major adverse cardio-
vascular events (MACE) versus standard care in people with
cardiovascular risk factors and impaired fasting glucose, impaired glu-
cose tolerance or type 2 diabetes [hazard ratio (HR) 1.02 (0.94;
1.11)95% CI].
3 In 2016, the final results from the Trial Comparing Car-
diovascular Safety of Insulin Degludec versus Insulin Glargine in
Patients with Type 2 Diabetes at High Risk of Cardiovascular Events
(DEVOTE) showed that degludec was non-inferior to glargine U100
with respect to the incidence of MACE (cardiovascular death, non-
fatal myocardial infarction or non-fatal stroke) in people with type
2 diabetes and high cardiovascular risk [HR 0.91 (0.78; 1.06)95% CI].
4
In the Liraglutide Effect and Action in Diabetes: Evaluation of Car-
diovascular Outcome Results (LEADER) trial, which included patients
with type 2 diabetes and high cardiovascular risk receiving standard
care, the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide
significantly reduced the relative risk of MACE by 13%, the risk of car-
diovascular death by 22% and the risk of all-cause mortality by 15% ver-
sus placebo.5 Liraglutide also reduced the proportion of patients
undergoing treatment intensification with antihyperglycaemic medica-
tions, including insulin, and the risks of severe hypoglycaemia and con-
firmed hypoglycaemia versus placebo.5 Based on the results of the
LEADER trial, liraglutide was recommended as a treatment option in the
treatment guidelines for patients with type 2 diabetes and established
cardiovascular disease.6,7
Consensus guidelines support the combination of a basal insulin
and a GLP-1RA as a treatment option for individuals with type
2 diabetes.7–9 For example, triple therapy, which can include the combi-
nation of metformin and a GLP-1RA with basal insulin (or oral antihy-
perglycaemic drugs), is recommended if a patient with type 2 diabetes
has not achieved his/her HbA1c target after 3 months of dual
therapy.7–9 Combining injectable therapies consisting of basal insulin
and a GLP-1RA, usually with metformin (with or without another non-
insulin agent), should also be considered if the patient has not achieved
the HbA1c target after 3 months of triple therapy using another
regimen,8 or when blood glucose is ≥16.7 mmol/L, HbA1c ≥ 10%
(≥86 mmol/mol) or the patient has symptoms of hyperglycaemia.7,8
Clinical studies evaluating insulin and GLP-1RA combination ther-
apy (both fixed and free combinations) for type 2 diabetes have
shown beneficial effects of this regimen on glycaemic control and
body weight, or weight neutrality, versus comparators.10–13 Some
insulin/GLP-1RA combinations also allow for reductions in existing
insulin doses.10–13 Furthermore, adding a GLP-1RA to insulin therapy
has been shown to decrease the risk of hypoglycaemia, even with
improved HbA1c levels.9,13–15
The aim of this post hoc analysis was to compare the associations
between concomitant liraglutide use versus no liraglutide use and the
occurrence of MACE and all-cause mortality among patients receiving
basal insulin (either degludec or glargine U100) in DEVOTE.
This analysis was also repeated for the individual MACE components,
serious adverse events and severe hypoglycaemic episodes.
2 | MATERIALS AND METHODS
2.1 | Trial design
The design of DEVOTE (ClinicalTrials.gov: NCT01959529) has been
described previously.4,16 The trial was conducted in accordance with
the Declaration of Helsinki and International Conference on Harmoni-
sation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) Guideline for Good Clinical Practice.17,18 The
protocol was approved by the independent ethics committee or insti-
tutional review board for each trial centre, and each participant pro-
vided written informed consent before any trial-related activities.4
Briefly, DEVOTE was a treat-to-target, randomized, double-blind,
active comparator-controlled cardiovascular outcomes trial conducted
in 20 countries.4,16 DEVOTE enrolled patients with type 2 diabetes
being treated with at least one oral or injectable antihyperglycaemic
agent who had HbA1c ≥7% (53 mmol/mol) or, if they had
HbA1c <7% (53 mmol/mol), were treated with ≥20 units/d of basal
insulin.4 Patients were eligible for inclusion if they were aged
≥50 years and had at least one co-existing cardiovascular condition or
chronic kidney disease, or if they were aged ≥60 years and had at
least one cardiovascular risk factor.4
From November 2013, 7637 participants were randomized 1:1 to
receive degludec or glargine U100 in a blinded fashion, both in identical
10 mL vials containing 100 U/mL, added to standard care and adminis-
tered once daily between dinner and bedtime.4 Randomized participants
could continue their pretrial antihyperglycaemic therapy, except for basal
and premix insulins, which were discontinued at randomization.4
The primary composite outcome was the time from randomiza-
tion to the first occurrence of cardiovascular death, non-fatal myocar-
dial infarction or non-fatal stroke (MACE). DEVOTE was designed to
continue until at least 633 MACE (confirmed by a central, blinded
Event Adjudication Committee) had occurred.4 Overall, the median
observation time was 1.99 (0-2.75) years.
Secondary outcomes included the time from randomization to
death from any cause (all-cause mortality), serious adverse events and
adjudicated severe hypoglycaemia.4 Severe hypoglycaemia was
defined, in accordance with criteria recommended by the American
Diabetes Association,19 as an episode requiring the assistance of
another person to actively administer carbohydrate or glucagon or to
take other corrective actions.4
2.2 | Statistical methods
In these post hoc analyses, HRs comparing concomitant liraglutide use
with no concomitant liraglutide use were calculated for the time to
the first occurrence of confirmed MACE (primary composite outcome)
and for the time to the first occurrence of confirmed individual MACE
components (cardiovascular death, non-fatal myocardial infarction and
non-fatal stroke). The same analyses were also applied to the first
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occurrence of confirmed all-cause mortality events, serious adverse
events and severe hypoglycaemic events including all randomized par-
ticipants. These analyses used a Cox regression model that adjusted
for treatment (degludec or glargine U100) as a fixed factor and liraglu-
tide use (Yes/No) at any time during the trial as a time-varying factor,
without interaction between the two factors. Thus, these analyses
account for patients' liraglutide use in a time-dependent manner by
handling initiation, interruption or discontinuation of liraglutide treat-
ment during the trial. Patients who did not experience the event of
interest in a particular analysis were right censored at the end of the
trial and contributed to the analysis with event-free exposure time
(Figure S1, Supporting Information).
Sensitivity analyses were conducted that adjusted for additional
baseline covariates, including age, sex, smoking status, race, diabetes
duration, cardiovascular risk group, insulin treatment, HbA1c, body
mass index (BMI), systolic blood pressure, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hepatic
impairment category and renal impairment category.
Further sensitivity analyses, conducted for MACE and all-cause
mortality, examined the influence of extending the time window in
which patients were considered to be receiving liraglutide after this
treatment had, in fact, been discontinued (by 7, 30, 60 or 90 days). This
potentially provided more conservative estimates of the effect of con-
comitant liraglutide use with each prolongation of the time window for
liraglutide use, by ascribing potential events occurring (shortly) after a
treatment pause to the liraglutide group. Lastly, a sensitivity analysis for
MACE and all-cause mortality was conducted where patients were con-
sidered to be liraglutide users from time of first initiation of liraglutide
use until the first event or right censoring (until end of trial or lost to
follow-up). These analyses thereby extended the time window in which
MACE and/or all-cause mortality events were considered to be con-
comitant with liraglutide use, although liraglutide use had been stopped.
These analyses are important to assess a potential tendency for patient
deterioration leading to changes in concomitant liraglutide use.
Due to the time-varying nature of the exposure for the present
analyses, patients could be included or excluded from the “concomi-
tant liraglutide use” group at different time points. Therefore, a tradi-
tional comparison of baseline characteristics was neither feasible nor
appropriate. However, comparing the characteristics of patients who
received liraglutide at any time during the trial and patients who never
used liraglutide during the trial can provide some information
(Table S1, Supporting Information).
Sensitivity analyses were also conducted to account for the possible
impact of concomitant sodium-glucose co-transporter-2 (SGLT-2) inhibi-
tor use on outcomes. For these analyses, patients who used SGLT-2
inhibitors at baseline were excluded from the concomitant liraglutide use
group and included in the no concomitant liraglutide use group.
3 | RESULTS
3.1 | Exposure to liraglutide during the trial
Among all randomized participants at baseline, only a limited number
of patients used a GLP-1RA (n = 604; 7.9%). Of these patients,
436 (72.2%) were receiving liraglutide at baseline. Based on the total
randomized population, 436 (5.7%) were receiving liraglutide at base-
line, 187 (2.4%) initiated liraglutide after baseline and 210 (2.7%) dis-
continued liraglutide after baseline. Mean liraglutide exposure from
randomization was 530.2 days [interquartile range: 476 days (Q1:
277; Q3: 753)] for all patients using liraglutide at any time across the
full analysis set irrespective of events occurred.
3.2 | Time to first MACE, individual MACE
components and all-cause mortality
Among patients who experienced events while exposed to liraglutide,
mean liraglutide exposure from randomization to the first confirmed
MACE was 302.1 days. The corresponding value for all-cause mortal-
ity was 348.8 days.
Concomitant liraglutide use was associated with a significantly
lower rate of MACE [HR 0.62 (0.41; 0.92)95% CI] compared with no
concomitant liraglutide use (Figure 1 and Table 1). Concomitant lira-
glutide use was also associated with a significantly lower rate of all-
cause mortality versus no concomitant liraglutide use [HR 0.50 (0.29;
0.88)95% CI] (Figure 1 and Table 2). This observation for MACE was
driven by lower rates of all three individual MACE components with
concomitant liraglutide versus no concomitant liraglutide use,
although only the rate of cardiovascular death was significantly lower
[HR for cardiovascular death 0.47 (0.23; 0.96)95% CI; HR for non-fatal
myocardial infarction 0.82 (0.49; 1.37)95% CI; HR for non-fatal stroke
0.56 (0.23; 1.37)95% CI] (Figure 1). Importantly, all of these results from
these analyses were observed while the overall effect of degludec ver-
sus glargine U100 seen in the primary analysis was preserved (data
not shown).
Among the 436 patients who were receiving liraglutide at base-
line, 27 first confirmed MACE were reported [3.1 events/100 patient-
years of observation (PYO)] compared with 654 first confirmed MACE
in patients not using liraglutide at baseline (4.7 events/100 PYO). Lira-
glutide use at baseline was associated with a significantly lower rate
of MACE [HR 0.65 (0.45; 0.96)95% CI, P = 0.03] compared with no lira-
glutide use, irrespective of the randomized basal insulin.
3.3 | Time to first serious adverse event and first
severe hypoglycaemic episode
Concomitant liraglutide use was associated with a significantly lower
rate of serious adverse events versus no concomitant liraglutide use
[HR 0.83 (0.70; 0.97)95% CI] (Figure 1). There was also a trend for a
lower rate of severe hypoglycaemia with concomitant liraglutide use
versus no concomitant liraglutide use, but the difference was not sta-
tistically significant [HR 0.79 (0.51; 1.24)95% CI] (Figure 1).
3.4 | Sensitivity analyses
HRs from the sensitivity analyses adjusted for additional baseline cov-
ariates were consistent with those obtained in the main analyses of
the time to first MACE, individual MACE components and all-cause
mortality events (Figure 2). However, after adjustment for additional
baseline covariates, the HR for one individual MACE component,
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cardiovascular death, with concomitant liraglutide use versus no con-
comitant liraglutide use, was no longer statistically significant,
although the HR was similar to that before adjustment [HR 0.52 (0.26;
1.06)95% CI; P = 0.0727].
The main analyses and sensitivity analyses adjusted for additional
baseline covariates provided similar results for the time to the first
serious adverse event (Figure 2). Similarly, consistent results were
obtained for the time to first severe hypoglycaemic episode following
adjustment for additional baseline covariates (Figure 2).
When the time window in which patients were considered to be
receiving liraglutide was extended by 7, 30, 60 or 90 days after the
actual stop date, concomitant liraglutide use was associated with sig-
nificantly lower rates of MACE and all-cause mortality in each sce-
nario, compared with no concomitant liraglutide use (Tables 1 and 2).
A similar result was found when the time window was extended maxi-
mally [i.e. patients were considered to be liraglutide users from time
of first use of liraglutide until the first event or right censoring (end of
trial or lost to follow-up)].











P-valueN Rate N Rate
Unadjusted main analysis 25 2.91 656 4.74 0.62 [0.41; 0.92] 0.0174
Sensitivity analyses
Adjusted for additional baseline covariates 25 2.91 656 4.74 0.56 [0.36; 0.88] 0.0119
Time window for liraglutide use extended by 7 days 27 3.13 654 4.73 0.66 [0.45; 0.97] 0.0366
Time window for liraglutide use extended by 30 days 28 3.20 653 4.73 0.68 [0.46; 0.99] 0.0434
Time window for liraglutide use extended by 60 days 29 3.25 652 4.72 0.69 [0.48; 1.00] 0.0499
Time window for liraglutide use extended by 90 days 29 3.20 652 4.73 0.68 [0.47; 0.98] 0.0393
Time window for liraglutide use extended maximally 33 3.07 648 4.76 0.64 [0.45; 0.92] 0.0140
Abbreviations: CI, confidence interval; HR, hazard ratio; glargine U100, insulin glargine 100 units/mL; MACE, major adverse cardiovascular events; N, num-
ber of events; Rate, events per 100 patient-years of observation.
Full analysis set (all randomized patients). HRs presented are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no
concomitant liraglutide use. HRs are based on a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial,
without interaction. Thus, the analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one
patient who experienced an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event.
FIGURE 1 Analyses of major clinical outcomes by time-varying liraglutide use. Full analysis set (all randomized patients). HRs presented are for
time to the first confirmed event (in days), comparing concomitant liraglutide use with no concomitant liraglutide use. HRs are based on a Cox
regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction. Thus, the analyses are
adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one patient who experienced an event
occurring on the same day as liraglutide initiation, half a day was added to the day of the event. CI, confidence interval; HR, hazard ratio; MACE,
major adverse cardiovascular events; N, number of events; Rate, events per 100 patient-years of observation
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When SGLT-2 inhibitor use was taken into account, similar
results to the main analysis and the sensitivity analyses adjusted for
baseline characteristics were observed (Figure S2, Supporting
Information).
3.5 | Patient characteristics
Overall, the group who received liraglutide at any time during the trial
(n = 623) and the group who never used liraglutide during the trial
(n = 7014) were similar at screening or baseline. At screening or









Liraglutide use vs. no
liraglutide use
HR [95% CI] Two-sided P-valueN Rate N Rate
Unadjusted main analysis 13 1.48 410 2.88 0.50 [0.29; 0.88] 0.0151
Sensitivity analyses
Adjusted for additional baseline covariates 13 1.48 410 2.88 0.55 [0.32; 0.96] 0.0362
Time window for liraglutide use extended by 7 days 13 1.47 410 2.88 0.50 [0.29; 0.87] 0.0143
Time window for liraglutide use extended by 30 days 13 1.45 410 2.88 0.49 [0.28; 0.86] 0.0122
Time window for liraglutide use extended by 60 days 13 1.42 410 2.89 0.48 [0.28; 0.84] 0.0102
Time window for liraglutide use extended by 90 days 13 1.40 410 2.89 0.48 [0.27; 0.83] 0.0084
Time window for liraglutide use extended maximally 19 1.72 404 2.88 0.57 [0.36; 0.91] 0.0184
Abbreviations: CI, confidence interval; HR, hazard ratio; glargine U100, insulin glargine 100 units/mL; N, number of events; Rate, events per 100 patient-
years of observation.
Full analysis set (all randomized patients). HRs presented are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no
concomitant liraglutide use. HRs are based on a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial,
without interaction. Thus, the analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one
patient who experienced an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event.
FIGURE 2 Adjusted analyses of major clinical outcomes by time-varying liraglutide use. Full analysis set (all randomized patients). HRs presented
are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no concomitant liraglutide use. HRs are based on a
Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial alongside additional baseline factors and
covariates, including age, sex, smoking status, race, diabetes duration, cardiovascular risk group, insulin treatment, HbA1c, BMI, systolic blood
pressure, LDL cholesterol, HDL cholesterol, hepatic impairment category and renal impairment category, all without interaction. Thus, the
analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one patient who experienced
an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event. CI, confidence interval; HR, hazard ratio;
MACE, major adverse cardiovascular events; N, number of events; Rate, events per 100 patient-years of observation, BMI, body mass index; LDL,
low-density lipoprotein; HDL, high-density lipoprotein
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baseline, the group who received liraglutide at any time during the
trial had numerically higher mean body weight and BMI, but numeri-
cally lower mean HbA1c, systolic blood pressure, total cholesterol and
LDL cholesterol than the group who never received liraglutide during
the trial. Additional patient characteristics and antihyperglycaemic and
cardiovascular medication use for these two groups at screening or
baseline are shown in Table S1, Supporting Information.
3.6 | Insulin use
After 24 months of randomized treatment, mean basal insulin doses
were the same for patients who did or did not receive liraglutide at
any time (0.7 ± 0.4 units/kg) (Figure S3 and Table S2, Supporting
Information). Mean bolus insulin doses used after 24 months of ran-
domized treatment were slightly lower in the group who received lira-
glutide at any time (0.5 ± 0.5 units/kg) than in the group who never
used liraglutide (0.6 ± 0.5 units/kg) (Figure S4 and Table S2, Support-
ing Information).
4 | DISCUSSION
These post hoc analyses of data from DEVOTE examined if the use of
liraglutide was associated with differences in the occurrence of MACE
and all-cause mortality in users of basal insulin (degludec or glargine
U100) with type 2 diabetes and high cardiovascular risk. Pooled data
from patients receiving degludec or glargine U100 showed that con-
comitant liraglutide use versus no concomitant liraglutide use was asso-
ciated with a 38% lower HR for MACE and a 50% lower HR for all-
cause mortality (both statistically significant), suggesting that the combi-
nation of liraglutide and basal insulin may be associated with a cardio-
vascular benefit. This is in line with the main finding from the LEADER
trial,5 where liraglutide significantly reduced the risks of MACE, cardio-
vascular death and all-cause mortality versus placebo in patients with
type 2 diabetes at high cardiovascular risk. Similarly, in a post hoc analy-
sis of basal insulin-treated patients in LEADER, treatment with liraglu-
tide versus placebo resulted in a cardiovascular risk reduction similar to
the results from the main trial and was also associated with a 50%
reduction in severe hypoglycaemia.20 In addition, in the present study a
range of sensitivity analyses were conducted for these outcomes,
including adjusting for additional baseline covariates and extending the
time window for liraglutide use. Results from these sensitivity analyses
were consistent with the main findings, suggesting that they are robust.
There are a number of observations from the LEADER trial that
provide supporting context for our analysis. Observations from our
post hoc analysis are supported by analyses of LEADER subgroups
receiving insulin with or without an oral antihyperglycaemic agent
(OHA) at baseline.5 In both of these LEADER subgroups, fewer
patients experienced MACE with liraglutide versus placebo, although
the differences did not reach statistical significance [HR for insulin
with OHA at baseline 0.89 (0.74; 1.06)95%CI; HR for insulin without
OHA at baseline 0.86 (0.63; 1.17)95% CI].
5 However, the LEADER trial
was not powered to detect significant differences in MACE in the post
hoc analysis because of the smaller number of patients included in
these subgroups versus the overall LEADER population.5 Additionally,
the observation that liraglutide reduced treatment intensification with
antihyperglycaemic medications during the LEADER trial, including
insulin,5 complicates the interpretation of these data.
Our analysis only included those patients treated with liraglutide
in DEVOTE and not all GLP-1RAs. This was primarily because of the
small proportion of patients who used a GLP-1RA that was not liraglu-
tide, which would not have allowed for a meaningful comparison.
Furthermore, the cardiovascular benefit of some other GLP-1RAs had
not been shown. On this basis, only those patients treated with
liraglutide were investigated. In the United States, liraglutide is
indicated to reduce the risk of MACE in adults with type 2 diabetes
and established cardiovascular disease.21 In addition, treatment guide-
lines were updated to mention liraglutide as the GLP-1RA to be used
in patients with type 2 diabetes and established cardiovascular
disease.6–8 The mechanisms underlying the reduction in MACE with lir-
aglutide have not been fully established, but an antiatherogenic effect
may be involved.22 Reductions in body weight and visceral fat,
improvements in insulin resistance associated with non-alcoholic stea-
tohepatitis, lipid profiles, anti-inflammatory effects and reductions in
hypoglycaemia and HbA1c may contribute to the cardiovascular bene-
fits of liraglutide.9,22,23 Moreover, current guidelines support the com-
bined use of a basal insulin and a GLP-1RA (both free and fixed
combinations) when individuals with type 2 diabetes require treatment
intensification.7–9 Therefore, as more patients use the GLP-1RA/basal
insulin combination, it is increasingly important to understand the car-
diovascular profile of these combinations, especially as patients with
type 2 diabetes are at high risk of cardiovascular events. The present
analysis revealed a 53% lower HR of cardiovascular death (significant)
and a 21% lower HR of severe hypoglycaemia (non-significant) with
concomitant liraglutide use versus no concomitant liraglutide use.
This study has several limitations. This was a post hoc analysis,
and our data show associations between liraglutide use and treatment
outcomes. In addition, as these were subgroup analyses, the 95% CIs
for the HRs comparing events of interest with liraglutide use versus
no liraglutide use were relatively wide, particularly for the individual
MACE components. Hence, the parameter estimates are somewhat
imprecise, but the patterns were consistent. Concomitant and non-
concomitant liraglutide use were not randomized groups in DEVOTE.
However, various sensitivity analyses supported the robustness of the
main finding. Furthermore, the sensitivity analyses did not account for
differences in insulin dose. However, basal insulin doses after
24 months of treatment were comparable in the concomitant and
non-concomitant liraglutide use groups, and therefore this factor
would be expected to have a limited impact on the analyses. In addi-
tion, as DEVOTE recruited and studied patients with type 2 diabetes
who were at high risk for cardiovascular events, our findings may be
more relevant to patients with established cardiovascular disease or
patients over 60 years of age with one or more cardiovascular risk
factors. Concomitant liraglutide use was associated with a lower risk
of adverse outcomes. Yet, it could be argued that prior to experienc-
ing a cardiovascular event a patient would feel unwell and may dis-
continue liraglutide, which would disfavour the control group and
potentially inflate the effect sizes associated with exposure. However,
the sensitivity analysis that applied an extended time window to lira-
glutide exposure in fact showed that the main findings were robust.
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Lastly, potential between-group differences were noted in the base-
line characteristics of patients who did or did not use liraglutide during
the trial at any time. These differences may be because of socioeco-
nomic factors and treatment goals for individual patients, which were
not possible to account for in this analysis. However, the sensitivity
analyses that adjusted for a range of additional covariates were con-
sistent with those obtained in the main analyses, suggesting that these
factors did not impact the prevalence of these outcomes. Neverthe-
less, residual confounding cannot be excluded.
This study also had a number of strengths. This analysis was
based on data from a large, double-blind, cardiovascular outcomes
trial, with independent adjudication of cardiovascular and severe
hypoglycaemic events. In addition, the sensitivity analyses that
adjusted for several baseline covariates and extended the time win-
dow for liraglutide use, maximally penalizing liraglutide use, support
our main findings. Lastly, the findings from this post hoc analysis are
in line with the overall findings from DEVOTE, LEADER, the LEADER
subanalyses and also data on cardiovascular risk markers seen with
degludec/liraglutide (IDegLira),4,24 thereby contributing significantly
to the body of evidence supporting the combination of liraglutide and
basal insulin in a free or fixed combination.
Overall, results from the present analyses indicate that the use of
liraglutide in combination with basal insulin is associated with a lower
cardiovascular risk, in terms of a significantly lower risk of first MACE
and all-cause mortality, compared with no liraglutide use. These
results, in line with the DEVOTE and LEADER primary results, provide
important and novel information for physicians prescribing a combina-
tion of insulin and liraglutide that may extend to fixed-dose insulin
and GLP-1RA combinations.
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